Bio/Pharma News

Sep 14, 2018
By Pharmaceutical Technology Editors
The companies will develop therapies targeting the in-vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform.
Sep 10, 2018
By Pharmaceutical Technology Editors
The collaboration will explore the potential of Dyadic’s gene-expression platform to produce multiple biologic vaccines and drugs.
Sep 06, 2018
By Pharmaceutical Technology Editors
The purchase of Novartis’ cystic fibrosis products TOBI Podhaler and TOBI solution is expected to strengthen Mylan’s global respiratory portfolio.
Sep 06, 2018
By Pharmaceutical Technology Editors
Novartis will sell selected portions of its Sandoz United States portfolio to Aurobindo Pharma USA for $900 million in cash, plus $100 million in potential earn-outs.
Sep 06, 2018
By Pharmaceutical Technology Editors
Emergent BioSolutions is set to acquire Adapt Pharma, a pharmaceutical company focused on addressing the opioid overdose and addiction crisis, in a deal worth up to $735 million.
Sep 04, 2018
By Pharmaceutical Technology Editors
Skin-focused company LEO Pharma acquired Bayer’s prescription treatment portfolio.
Aug 30, 2018
By Pharmaceutical Technology Editors
The European Commission (EC) has approved GlaxoSmithKline’s (GSK) Nucala (mepolizumab) as an add-on treatment for severe refractory eosinophilic asthma in pediatric patients six to 17 years old.
Aug 29, 2018
By Pharmaceutical Technology Editors
Bristol-Myers Squibb appointed a new executive vice-president and chief commercial officer from within the company, effective immediately.
Aug 28, 2018
By Pharmaceutical Technology Editors
The European Commission (EC) has approved Novartis’ chimeric antigen receptor T cell (CAR-T) cell therapy Kymriah for the treatment of B-cell acute lymphoblastic leukemia and relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Aug 27, 2018
By Pharmaceutical Technology Editors
The acquisition will support Novo Nordisk’s development of glucose-responsive insulins.
native1_300x100
lorem ipsum